WindMIL Therapeutics, based in Baltimore, Maryland, filed a form D with the U.S. Securities and Exchange Commission, indicating it had raised $32.53 million in equity financing. The Series B round was led by QiMing USA Venture Partners, the new U.S. entity of China company QMing. There was a Series A round worth $11 million.

WindMIL focuses on methods of extracting, activating and expanding bone marrow derived T-cells to be used in immunotherapies of cancer. Its process is called Marrow Infiltrating Lymphocytes or MILs. Derived from bone marrow, a natural reservoir for memory T cells, MILs are uniquely applicable for autologous cell therapy. The company’s lead program is in a Phase IIb clinical trial in high-risk multiple myeloma. It has additional programs in solid tumors using MILs.